Overall (N = 14,461) | Non-Squamous (N = 9,359) | Squamous (N = 2,527) | Unspecified Non-Small Cell Cancer (N = 471) | Not Documented (N = 2,104) | |
EGFR Status, N (%) | |||||
Patients tested | 5132 (35.5) | 4456 (47.6) | 358 (14.2) | 120 (25.5) | 198 (9.4) |
Negative | 4098 (79.9) | 3500 (78.5) | 330 (92.2) | 111 (92.5) | 157 (79.3) |
Positive1 | 1016 (19.8) | 938 (21.1) | 28 (7.8) | 9 (7.5) | 41 (20.7) |
Tested, but result unknown | 18 (0.4) | 18 (0.4) | 0 | 0 | 0 |
No documented testing | 9329 (64.5) | 4903 (52.4) | 2169 (85.8) | 351 (74.5) | 1906 (90.6) |
ALK Status, N (%) | |||||
Patients tested | 4752 (32.9) | 4121 (44.0) | 337 (13.3) | 119 (25.3) | 175 (8.3) |
Negative | 4448 (93.6) | 3849 (93.4) | 322 (95.5) | 111 (93.3) | 166 (94.9) |
Positive | 204 (4.3) | 189 (4.6) | 8 (2.4) | 1 (0.8) | 6 (3.4) |
Tested, but result unknown | 100 (2.1) | 83 (2.0) | 7 (2.1) | 7 (5.9) | 3 (1.7) |
No documented testing | 9709 (67.1) | 5238 (56.0) | 2190 (86.7) | 352 (74.7) | 1929 (91.7) |
ROS1 Status, N (%) | |||||
Patients tested | 820 (5.7) | 712 (7.6) | 91 (3.6) | 15 (3.2) | 2 (0.1) |
Negative | 797 (97.2) | 690 (96.9) | 91 (100.0) | 14 (93.3) | 2 (100.0) |
Positive | 23 (2.8) | 22 (3.1) | 0 | 1 (6.7) | 0 |
No documented testing | 13,641 (94.3) | 8647 (92.4) | 2436 (96.4) | 456 (96.8) | 2102 (99.9) |
PD-L1 Status, N (%) | |||||
Patients tested | 831 (5.7) | 673 (7.2) | 135 (5.3) | 19 (4.0) | 4 (0.2) |
Negative | 487 (58.6) | 402 (59.7) | 78 (57.8) | 7 (36.8) | 0 |
Positive | 344 (41.4) | 271 (40.3) | 57 (42.2) | 12 (63.2) | 4 (100.0) |
No documented testing | 13,630 (94.3) | 8686 (92.8) | 2392 (94.7) | 452 (96.0) | 2100 (99.8) |
BRAF Status, N (%) | |||||
Patients tested | 16 (0.1) | 15 (0.2) | 0 | 1 (0.2) | 0 |
Negative | 13 (81.3) | 13 (86.7) | 0 | 0 | 0 |
Positive | 3 (18.8) | 2 (13.3) | 0 | 1 (100.0) | 0 |
No documented testing | 14,445 (99.9) | 9344 (99.8) | 2527 (100.0) | 470 (99.8) | 2104 (100.0) |